#USA #NASDAQ #PTC Therapeutics #stock options #Warren

PTC Therapeutics Announces Inducement Grants

Warren, N.J., October 27, 2025 — PTC Therapeutics, Inc. (NASDAQ: PTCT) has made headlines with the announcement of significant inducement grants to two new employees as part of their compensation package. On October 23, 2025, the company approved the issuance of non-statutory stock options and restricted stock units (RSUs) that are likely to play a crucial role in attracting talent to the organization.

Details of the Grants

According to the information released, PTC Therapeutics has granted stock options for a total of 2,000 shares of its common stock and 1,990 RSUs to the new hires. Each RSU grants the right to receive one share of common stock upon vesting. These awards were authorized by PTC's Compensation Committee in compliance with the Nasdaq inducement grant exception, specifically under Nasdaq Listing Rule 5635(c)(4). This rule allows companies to give inducement grants to new employees to help in recruitment efforts, especially in competitive fields like biopharmaceuticals.

The stock options come with an exercise price of $66.80 per share, reflecting the closing price of PTC’s common stock on the day of the grant. The options have a term of 10 years, with vesting schedules set to reward employees over a four-year period. The structure stipulates that 25% of the shares will vest on the first anniversary of the employee’s hire date, with an incremental 6.25% vesting every three months thereafter, contingent on the continued service of the employees.

The RSUs will follow a similar vesting timeline, with 25% vesting at each annual anniversary until fully vested, again dependent on the ongoing employment of the individuals.

Importance of the Inducement Grants

This move by PTC Therapeutics underscores the company’s commitment to securing top talent in an industry that is not just competitive but crucial for the ongoing development of treatments for rare disorders. By employing equity incentives such as stock options and RSUs, PTC seeks to not only attract skilled professionals but also to align their interests with those of the company and its shareholders.

About PTC Therapeutics

PTC Therapeutics is recognized as a global biopharmaceutical company dedicated to the discovery, development, and commercialization of innovative medicines aimed at addressing rare disorders faced by both children and adults. With an extensive and diverse pipeline of transformative medicines, PTC is committed to enhancing access to industry-leading treatments for patients who have unmet medical needs. Their strategic approach involves leveraging scientific insights and a robust commercial infrastructure to maximize value for all stakeholders, especially patients.

To learn more about PTC and their initiatives, interested parties are encouraged to visit www.ptcbio.com and follow them on their social media platforms including Facebook, X, and LinkedIn for the latest updates.

Contact Information

For investors, Ellen Cavaleri is available at +1 (615) 618-8228 or via email at [email protected]. For media inquiries, Jeanine Clemente can be contacted at +1 (908) 912-9406 or through email at [email protected].